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The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory 
disease, has infected over 2.3 million people, killed over 160,000, and caused 
worldwide social and economic disruption1,2. There are currently no antiviral drugs 
with proven clinical efficacy, nor are there vaccines for its prevention, and these 
efforts are hampered by limited knowledge of the molecular details of SARS-CoV-2 
infection. To address this, we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 
proteins in human cells and identified the human proteins physically associated with 
each using affinity-purification mass spectrometry (AP-MS), identifying 332 
high-confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among 
these, we identify 66 druggable human proteins or host factors targeted by 69 
compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical 
compounds). Screening a subset of these in multiple viral assays identified two sets 
of pharmacological agents that displayed antiviral activity: inhibitors of mRNA 
translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further 
studies of these host factor targeting agents, including their combination with drugs 
that directly target viral enzymes, could lead to a therapeutic regimen to treat 
COVID-19.
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SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA betac-
oronavirus of the family Coronaviridae3,4. Coronaviruses infecting hum 
ans historically included several mild common cold viruses, includ-
ing hCoV-OC43, HKU, and 229E5. However, over the past two decades, 
highly pathogenic human coronaviruses have emerged, including 
SARS-CoV in 2002 with 8,000 cases worldwide and a death rate of ~10%, 
and MERS-CoV in 2012, with 2,500 confirmed cases and a death rate of 
36%. Infection with these highly pathogenic coronaviruses can result 
in Acute Respiratory Distress Syndrome (ARDS), which may lead to 
long-term reduction in lung function, arrhythmia, or death. Compared 
to MERS-CoV or SARS-CoV, SARS-CoV-2 has a lower case-fatality rate 
but spreads more efficiently6, making it difficult to contain. To devise 
therapeutic strategies to counteract SARS-CoV-2 infection and the 
associated COVID-19 (Coronavirus Disease 2019) pathology, it is crucial 
to understand how this coronavirus hijacks the host during infection, 
and to apply this knowledge towards developing new drugs and repur-
posing existing ones.
So far, no clinically available antiviral drugs have been developed 
for SARS-CoV, SARS-CoV-2 or MERS-CoV. Clinical trials are ongoing for 
treatment of COVID-19 with the nucleoside analog RNA-dependent RNA 
Polymerase (RdRP) inhibitor Remdesivir7, and recent data suggests a 
new nucleoside analog may be effective against SARS-CoV-2 infection 
in laboratory animals8. Clinical trials on several vaccine candidates 
are also underway9, as are trials of repurposed compounds inhibiting 
the human protease TMPRSS210. We believe there is great potential in 
systematically exploring the host dependencies of the SARS-CoV-2 
virus to identify other host proteins already targeted by existing drugs. 
Therapies targeting the host-virus interface, where the emergence 
of mutational resistance is arguably less likely, could potentially pre-
sent durable, broad-spectrum treatment modalities11. Unfortunately, 
limited knowledge of the molecular details of SARS-CoV-2 infection 
precludes a comprehensive evaluation of small molecule candidates 
for host-directed therapies. We sought to address this gap by systemati-
cally mapping the interaction landscape between SARS-CoV-2 proteins 
and human proteins.
Cloning and expression of predicted SARS-CoV-2 
proteins
Sequence analysis of SARS-CoV-2 isolates suggests that the 30kb 
genome encodes as many as 14 open reading frames (Orfs). The 
Orf1a / Orf1ab encodes a polyprotein, which is auto-proteolytically 
processed into 16 non-structural proteins (Nsp1-16) that form the 
replicase / transcriptase complex (RTC) (Fig. 1a). The RTC consists 
of multiple enzymes, including the papain-like protease (Nsp3), the 
main protease (Nsp5), the Nsp7-Nsp8 primase complex, the primary 
RNA-dependent RNA polymerase (Nsp12), a helicase / triphosphatase 
(Nsp13), an exoribonuclease (Nsp14), an endonuclease (Nsp15), and 
N7- and 2’O-methyltransferases (Nsp10/Nsp16)1,12,13. At the 3’ end of the 
viral genome, as many as 13 Orfs are expressed from nine predicted 
sub-genomic RNAs. These include four structural proteins: Spike (S), 
Envelope (E), Membrane (M) and Nucleocapsid (N)13, and nine putative 
accessory factors (Fig. 1a)1,12. The SARS-CoV-2 genome is very similar 
to SARS-CoV. While both have an Orf1ab encoding 16 predicted Nsps 
as well as the four typical coronavirus structural proteins, they differ 
in their complement of 3’ Orfs: SARS-CoV-2 possesses an Orf3b and 
Orf10 with limited detectable homology to SARS-CoV1,12 (Extended 
Data Fig. 1a).
Mature Nsps, with the exception of Nsp3 and Nsp16, and all predicted 
proteins expressed from other SARS-CoV-2 Orfs (27 proteins plus one 
mutant) were codon optimized and cloned into a mammalian expres-
sion vector with a 2xStrep affinity tag fused for affinity purification 
mass spectrometry (AP-MS) based proteomics upon expression in 
HEK293T/17 cells. High-confidence interactors were identified using 
SAINTexpress and MiST scoring algorithms14,15.
To verify viral protein expression, we performed an anti-Strep west-
ern blot on input cell lysate, and with the exception of Nsp4, Nsp6, 
Nsp11, and Orf3b, we observed bands consistent with predicted protein 
sizes (24 of 28 constructs; Extended Data Fig. 1b). Despite the lack of 
detection via western blot, we detected expression of viral peptides 
Nsp4, Nsp6, and Orf3b in the proteomic analysis. The fourth construct 
not confirmed by western blot, the small peptide Nsp11, had a predicted 
molecular mass of 4.8 kDa (including tag) but an apparent mass of 
approximately 30 kDa (Extended Data Fig. 1b).
Alignment of 2,784 SARS-CoV-2 sequences revealed a premature 
stop codon at position 14 of Orf3b in 17.6% of isolates (Extended Data 
Fig. 1c), and two mutations were also observed resulting in premature 
stop codons in Orf9c (Extended Data Fig. 1d). These data suggest that 
Orf3b and Orf9c might not be bonafide SARS-CoV-2 reading frames, or 
are dispensable for replication. Pending a comprehensive evaluation 
of viral protein expression, we nevertheless proceeded with analysis 
for all possible viral proteins. Out of the 27 bait proteins (Fig. 1b), the 
affinity purification of Orf7b showed an unusually high number of 
background proteins and was therefore excluded from protein inter-
action analysis. We have thus far sent these plasmids to almost 300 
laboratories in 35 countries.
Global analysis of SARS-CoV-2 host interacting proteins
Our AP-MS analysis identified 332 high-confidence protein interactions 
between SARS-CoV-2 proteins and human proteins, observing correla-
tion between replicate experiments of each viral bait (R = 0.46 - 0.72) 
(Extended Data Fig. 2, Supplementary Tables 1 and 2). We studied the 
interacting human proteins in regards to their cell biology, anatomical 
expression patterns, expression changes during SARS-CoV-2 infection16 
and in relation to other maps of host-pathogen interacting proteins15,17 
(Fig. 2a). We analyzed each viral protein for Gene Ontology enrichment 
(Fig. 2b, Extended Data Fig. 3), identifying the major cell processes of 
the interacting proteins, including lipoprotein metabolism (S), nuclear 
transport (Nsp7), and ribonucleoprotein complex biogenesis (Nsp8). 
To discover potential binding interfaces, we enriched for domain fami-
lies within the interacting proteins of each viral bait (Extended Data 
Fig. 4). For instance, DNA polymerase domains are enriched among 
Nsp1 interactors, while bromodomains and extra-terminal domain 
(BET) family domains are enriched among E interactors (see Supple-
mentary Discussion and Methods).
While the cell line used for these AP-MS experiments, HEK-293T/17, is 
permissive to SARS-CoV-2 infection18, it does not represent the primary 
physiological site of infection, lung tissue. From 29 human tissues19, we 
identified the lung as the tissue with the highest expression of the prey 
proteins relative to the average proteome (Fig. 2c). Consistent with 
this, the interacting proteins were enriched in the lung relative to other 
tissues (Extended Data Fig. 5a), and compared to overall RefSeq gene 
expression in the lung (median=3.198 TPM) interactors were expressed 
at a higher level (median=25.52 TPM, p=0.0007; t-test) (Extended Data 
Fig. 5b), supporting the hypothesis that SARS-CoV-2 preferentially 
hijacks proteins expressed in lung tissue.
We also studied the evolutionary properties of the host proteins 
(Supplementary Table 3 and Supplementary Discussion and Meth-
ods) and analyzed protein abundance changes during SARS-CoV-2 
infection16. We calculated, when possible, the correlation between 
changes in abundance of viral proteins and their human interaction 
partners across four time points. Interacting pairs typically have 
stronger correlated changes than other pairs of viral-human proteins 
(Fig. 2d, KS test p-value=4.8e−05), arguing that the AP-MS derived 
interactions are relevant for the target tissue and the infection context. 
Comparing our SARS-CoV-2 interaction map with those for ten other 
pathogens (Fig. 2e), West Nile Virus (WNV)20 and Mycobacterium tuber-














The association with Mtb is particularly interesting considering it also 
infects lung tissue.
The SARS-CoV-2 interactome reveals novel aspects of 
SARS-CoV-2 biology
Our study highlighted interactions between SARS-CoV-2 proteins and 
human proteins involved in several complexes and biological processes 
(Fig. 3). These included DNA replication (Nsp1), epigenetic and gene 
expression regulators (Nsp5, Nsp8, Nsp13, E), vesicle trafficking (Nsp2, 
Nsp6, Nsp7, Nsp10, Nsp13, Nsp15, Orf3a, E, M, Orf8), lipid modification 
(Spike), RNA processing and regulation (Nsp8, N), ubiquitin ligases 
(Orf10), signaling (Nsp8, Nsp13, N, Orf9b), nuclear transport machinery 
(Nsp9, Nsp15, Orf6), cytoskeleton (Nsp1, Nsp13), mitochondria (Nsp4, 
Nsp8, Orf9c), and extracellular matrix (Nsp9).
Approximately 40% of SARS-CoV-2 interacting proteins were associ-
ated with endomembrane compartments or vesicle trafficking path-
ways. Host interactions of Nsp8 (signal recognition particle; SRP), Orf8 
(endoplasmic reticulum protein quality control), M (ER morphology), 
and Nsp13 (centrosome and golgi organization) may facilitate the dra-
matic reconfiguration of ER/Golgi trafficking during coronavirus infec-
tion, and interactions in peripheral compartments by Nsp2 (WASH), 
Nsp6 and M (vacuolar ATPase), Nsp7 (Rabs), Nsp10 (AP2), E (AP3), and 
Orf3a (HOPS) may also modify endomembrane compartments to favor 
coronavirus replication. Nsp6 and Orf9c interact with Sigma receptors 
that are implicated in lipid remodeling and ER stress response; these 
proteins interact with many human drugs (see below).
Trafficking into the ER and mitochondria may also be impacted by the 
SARS-CoV-2 main protease, Nsp5. We identified one high-confidence 
interaction of wild-type Nsp5 with the epigenetic regulator histone 
deacetylase 2 (HDAC2), and predicted a cleavage site between the 
HDAC domain and the nuclear localization sequence (Extended Data 
Fig. 6a-d), suggesting that Nsp5 may inhibit HDAC2 transport into the 
nucleus, potentially impacting HDAC2’s mediation of inflammation and 
interferon response22,23. We also identified an interaction of catalytically 
dead Nsp5 (C145A) with tRNA methyltransferase 1 (TRMT1), which is 
responsible for the dimethylation of guanosine (m2,2G) on both nuclear 
and mitochondrial tRNAs24. We predict TRMT1 is also cleaved by Nsp5 
(Extended Data Fig. 6a-d), removing its zinc finger and nuclear localiza-
tion signal, likely resulting in an exclusively mitochondrial localization.
SARS-CoV-2 interacts with multiple innate immune 
pathways
Several innate immune signaling proteins are targeted by SARS-CoV-2 
viral proteins. The IFN pathway is targeted by Nsp13 (TBK1 and TBKBP1), 
Nsp15 (RNF41 / Nrdp1) and Orf9b (TOMM70); while the NF-κB pathway 
was targeted by Nsp13 (TLE1, 3, and 5) Orf9c (NLRX1, F2RL1, NDFIP2). 
Also, two other E3 ubiquitin ligases that regulate antiviral innate 
immune signaling, TRIM59 and MIB1, are bound by Orf3a and Nsp9, 
respectively25,26
We also identified interactions between SARS-CoV-2 Orf6 and 
NUP98-RAE1 (Fig. 4a i), an interferon-inducible mRNA nuclear export 
complex27 that is hijacked or degraded by multiple viruses includ-
ing VSV, Influenza-A, KSHV, and Polio, and is a restriction factor for 
Influenza-A infection28–31. The X-ray structure of VSV M protein com-
plexed with NUP98-RAE132 reveals key binding interactions, including a 
buried methionine residue on the M protein packing into a hydrophobic 
pocket in RAE1, and neighboring acidic residues interacting with a basic 
patch on the NUP98-RAE1 complex32. These features are also present in 
a conserved motif in the C-terminal region of SARS-CoV-2 Orf6 (Fig. 4a 
ii-iv, Extended Data Fig. 7a,b), providing a structural hypothesis for 
the observed interaction. Orf6 of SARS-CoV antagonizes host inter-
feron signaling by perturbing nuclear transport33, and the NUP98-RAE1
interaction with Orf6 may perform the same function for SARS-CoV-2.
SARS-CoV-2 interacts with the host translation 
machinery
SARS-CoV-2 nucleocapsid (N) binds the stress granule (SG) proteins 
G3BP1/2, and to other host mRNA binding proteins including the 
mTOR-regulated translational repressor LARP1, the protein kinases 
CK2, and mRNA decay factors UPF1 and MOV10 (Fig. 4b i). Manipulation 
of SG and related RNA biology is common among coronaviridae34–36 and 
stress granule formation is thought to be a primarily antiviral response. 
The promotion of G3BP aggregation by eIF4A inhibitors28,37 may par-
tially explain their antiviral activity (see below).
All coronavirus mRNAs rely on cap-dependent translation to produce 
their proteins, a process enhanced in trans by the SARS-CoV N protein38. 
Key eIF4F-cap binding complex constituents – the cap binding protein 
eIF4E, scaffold protein eIF4G, and the DEAD-box helicase eIF4A – are 
candidates for therapeutic targeting of coronaviruses39,40. Therapeutic 
targeting (Fig. 4b ii-iii) of viral translation by interfering with the eIF4F 
complex formation or the interactions between viral proteins N, Nsp2, 
Nsp8, and the translational machinery may have therapeutic benefits 
(see below and Fig. 6).
Cotranslational entry into the secretory pathway is a potential 
target for SARS-CoV-2 inhibition. Up to ten SARS-CoV-2 proteins are 
predicted to undergo ER membrane insertion mediated by the Sec61 
translocon, which localizes to SARS-CoV replication complexes41. 
Furthermore, high-confidence interactions between Nsp8 and three 
SRP components suggest viral hijacking of Sec61-mediated protein 
translocation into the ER. Sec61 inhibitors of protein biogenesis 
such as PS3061 (Fig. 4b iv), previously shown to inhibit other envel-
oped RNA viruses42,43, may also block SARS-CoV-2 replication and 
assembly.
The novel Orf10 of SARS-CoV-2 interacts with a Cullin 
ubiquitin ligase complex
Viruses commonly hijack ubiquitination pathways for replication and 
pathogenesis44. The novel Orf10 of SARS-CoV-2 interacts with members 
of a Cullin 2 (CUL2) RING E3 ligase complex (Fig. 4c i), specifically the 
CUL2ZYG11B complex. ZYG11B is the highest scoring protein in the Orf10 
interactome, suggesting a direct interaction. Despite its small size 
(38aa), Orf10 appears to contain an alpha helical region (Fig 4c ii) that 
could be adopted in complex with CUL2ZYG11B. The ubiquitin transfer to 
a substrate requires neddylation of CUL2 via NEDD8-activating enzyme 
(NAE), a druggable target45 (Fig. 4c iii). Orf10 may bind to the CUL2ZYG11B 
complex and hijack it for ubiquitination and degradation of restriction 
factors, or alternatively, ZYG11B may bind the N-terminal glycine in 
Orf10 to target it for degradation31.
SARS-CoV-2 envelope interacts with bromodomain 
proteins
We found that the transmembrane E protein, likely resident on ERGIC 
and golgi membranes, binds to BRD2 and BRD4 (Fig. 4d i), mem-
bers of the bromodomain and extra-terminal (BET) domain family 
of epigenetic readers that bind acetylated histones to regulate gene 
transcription46. The C-terminal region of E mimics the N-terminal 
segment of histone H3, a known interacting partner of bromodo-
mains47. Importantly, this region of E is highly conserved in SARS 
and bat coronaviruses, suggesting conserved function (Fig. 4d ii). A 
similar short peptide motif has also been identified in the NS1 protein 
of influenza A H3N2 strain, where it interferes with transcriptional 
processes that support antiviral response47,48. Bromodomain inhibi-
tors (iBETs) might disrupt the interaction between protein E and 
BRDs (Fig. 4d iii).
For a more comprehensive overview of virus-host interactions, 













Identification of existing drugs targeting SARS-CoV-2 
human host factors
To disrupt the SARS-CoV-2 interactome, we sought ligands of the human 
interacting proteins (Methods). Molecules were prioritized by the 
statistical significance of the interaction between the human and viral 
proteins; by their status as approved drugs, investigational new drugs 
(INDs, “clinical”), or as preclinical candidates; by their selectivity; and 
by their availability (Supplementary Tables 4 and 5). Chemoinformatics 
searches from the IUPHAR/BPS Guide to Pharmacology (2020-3-12) and 
the ChEMBL25 database on the human interactors yielded 16 approved 
drugs, 3 investigational new drugs (clinical), and 18 pre-clinical can-
didates (Supplementary Table 4); while target- and pathway-specific 
literature search revealed 13 approved drugs, 9 investigational new 
drugs (clinical), and 10 preclinical candidates (Supplementary Table 5). 
Of the 332 human targets that interact with the viral bait proteins with 
high significance (Fig. 3), 63 have 69 drugs/INDs/preclinical molecules 
that modulate them and can be overlaid on our protein interaction 
network (Fig. 5).
Antiviral activity of host-directed drugs and 
compounds
We next investigated the antiviral activity of these drugs and 
compounds, employing two viral assays (Fig.  6a). First, at Mt 
Sinai Hospital in New York, we developed a medium-throughput 
immunofluorescence-based assay (detecting the viral NP protein) to 
screen 37 compounds for inhibition of SARS-CoV-2 infection in the 
Vero E6 cell line. Second, at the Institut Pasteur in Paris, viral RNA was 
monitored using qRT-PCR upon treatment with 44 drugs and com-
pounds. Together, both locations tested 47 of the 69 compounds we 
identified, plus 13 to expand testing at the SigmaR1/R2 receptors and 
mRNA translation targets, and 15 additional molecules prioritized 
by other methods (see Methods and Supplementary Table 6). Viral 
growth and cytotoxicity were monitored at both institutions (Extended 
Data Figs. 8 & 9; Supplementary Table 6). Two classes of molecules 
emerged as effectively reducing viral infectivity: protein biogenesis 
inhibitors (zotatifin, ternatin-4, and PS3061; Fig. 6b, Extended Data 
Fig. 9) and ligands of the Sigma1 and Sigma2 receptors: haloperidol, 
PB28, PD-144418 and hydroxychloroquine, which is undergoing clini-
cal trials in COVID-19 patients49; we also subsequently found the Sig-
maR1/R2 active drugs clemastine, cloperastine, and progesterone 
(Fig. 6c, Extended Data Fig. 9) and the clinical molecule siramesine 
(Extended Data Figure 9) to be antiviral. TCID50 assays on supernatants 
from infected cells treated with PB28 (IC90 0.278 μM) and zotatifin (IC90 
0.037 μM) revealed a more potent inhibition than was observed in the 
NP-staining assay (Fig. 6d). Interestingly, in this assay, PB28 was ~20 
times more potent than hydroxychloroquine (IC90 5.78 μM).
To better understand the mechanism by which these inhibitors exert 
their antiviral effects, we performed a time course assay where the 
drugs were added at different times relative to infection (Fig. 6e). This 
was a single cycle infection at high MOI (2) over the course of 8 hours, 
where the drugs were either added 2 hours prior to infection or at 0, 
2 or 4 hours post infection. PB28, zotatifin, and hydroxychloroquine 
all decreased the detection of the viral NP protein even in this single 
cycle assay, indicating the antiviral effect occurs before viral egress 
from the cell (Fig. 6e). Furthermore, all three molecules inhibited NP 
expression when added up to 4 hours post-infection, after viral entry 
has occurred. Thus, these molecules seem to exert their antiviral effect 
during viral replication.
Coronaviruses rely on cap-dependent mRNA translation through the 
host translation machinery. eIF4H, an interactor of Nsp9, is a partner of 
eIF4A, and we observed a strong antiviral effect by the eIF4A inhibitor 
zotatifin (Fig. 6b), which is currently in a phase I clinical trial for cancer 
therapy. We also observed potent antiviral effects of the elongation 
factor-1A (eEF1A) inhibitor ternatin-450 (Fig. 6b), which may suggest that 
the rate of translation elongation is critical for obtaining optimal levels 
of viral proteins. Of note, the eEF1A inhibitor Plitidepsin is used clini-
cally in multiple myeloma patients51. Multiple SARS-CoV-2 proteins are 
predicted to undergo SRP- and Sec61-mediated co-translational inser-
tion into the endoplasmic reticulum, and SRP19/54/72 were identified 
as Nsp8 interacting proteins (Fig. 3). Consistent with previous studies 
of flaviviruses42, the Sec61 inhibitor PS3061 also blocked SARS-CoV-2 
replication (Extended Data Fig. 9). The two translation inhibitors had 
cytostatic effect in uninfected Vero cells, which are immortalized cell 
lines with indefinite proliferative capacity, harboring mutations in key 
cell cycle inhibitors. Unsurprisingly, these cells are more sensitive to 
anti-cancer compounds, which affect the cell cycle state of immortal-
ized cells more strongly than normal cells. A critical question going 
forward is whether these or related inhibitors of viral protein biogen-
esis will show therapeutic benefit in COVID-19 patients. Plitidepsin is 
currently under consideration by the Spanish Medicines Agency for a 
Phase II trial in hospitalized COVID-19 patients.
Molecules that target the Sigma1 and Sigma2 receptors perturb the 
virus through different mechanisms than the translation inhibitors, 
potentially including cell stress response52. These molecules are also 
active against other aminergic receptors, but the only ones shared 
among all of them are the Sigma1 and Sigma2 receptors (Fig. 6f), into 
which these drugs can be readily modeled (Extended Data Fig. 10a). 
For instance, the antipsychotic haloperidol inhibits the dopamine D2 
and histamine H1 receptors, while clemastine and cloperastine are 
themselves antihistamines; each also are Sigma receptor ligands with 
antiviral activity (Fig. 6c). Conversely, the antipsychotic olanzapine, 
which also inhibits H1 and D2 receptors, has little Sigma receptor activ-
ity and is not antiviral (Extended Data Fig. 10b). Which of the Sigma 
receptors might be most responsible for activity remains uncertain, 
as does the role of pharmacologically-related targets, such as EBP and 
related sterol isomerases, whose ligand recognition resembles those of 
the Sigma receptors. Intriguingly, the Sigma1 benzomorphan agonist, 
dextromethorphan, actually has pro-viral activity (Fig. 6g), further 
supporting the role of these receptors in viral infection. Overall, two 
features merit emphasis. First, several of the Sigma active molecules, 
like clemastine, cloperastine, and progesterone, are approved drugs 
with a long history in human therapy. Many other widely-used drugs, 
active on Sigma receptors, remain to be tested; and indeed, several 
such as astemizole, which we find to be a 95 nM Sigma2 receptor ligand 
(Extended Data Fig. 11), verapamil, and amiodarone, have been reported 
by others to be active in viral replication assays, though this has not been 
linked to their Sigma receptor activity53,54. Second, the Sigma ligands 
have a clear separation between antiviral and cytotoxic effects (Fig. 6b 
and c), and ligands like PB28 have substantial selectivity for the Sigma 
receptors versus side-effect targets, like the hERG ion channel. Indeed, 
the lack of selectivity of chloroquine and hydroxychloroquine versus 
hERG (Fig. 6h) and other off-targets (Extended Data Fig. 12) may be 
related to the cardiac adverse drug reactions55 that have limited their use.
Discussion
In this study, we have identified 332 high-confidence SARS-CoV-2-human 
PPIs connected to multiple biological processes, including protein 
trafficking, translation, transcription and ubiquitination regulation. 
Against these targets we found 69 ligands, including FDA approved 
drugs, compounds in clinical trials, and preclinical compounds. Anti-
viral tests in two different laboratories reveal two broad sets of active 
drugs and compounds; those impinging on translation, and those 
modulating Sigma1 and Sigma2 receptors. Within these sets are at 
least five targets and over ten different chemotypes, suggesting a rich 
landscape for optimization.
The chemo-proteomic analysis that emerges from this study not only 














interactome, it provides a context for interpreting their mechanism of 
action. The potent efficacy of the translation inhibitors on viral infec-
tivity—in the 10 to 100 nM range—makes these molecules attractive 
as candidate antivirals, and also highlights this pathway as a point of 
intervention. While the mechanism of action of the drugs targeting the 
Sigma1 and Sigma2 receptors remains less defined, their activity as both 
anti- and pro-viral agents is mechanistically suggestive. The relatively 
strong efficacy of PB28, at 280 nM IC90 in the viral titer assay, and its high 
selectivity against off-targets, suggests that molecules of this class may 
be optimized towards therapeutics. Whereas it is unclear that approved 
drugs like clemastine and cloperastine, which are used as antihista-
mines and antitussives, have pharmacokinetics suitable for antiviral 
therapy, nor are they free of binding to side-effect targets (Fig. 6f and 
Extended Data Fig. 12), they have been used for decades. We do caution 
against their use outside of controlled studies, due to their side-effect 
liabilities. By the same standard, we find that the widely used antitus-
sive dextromethorphan harbors proviral activity and therefore its use 
should merit caution and further study in the context of COVID-19. 
More positively, there are dozens of approved drugs that are active 
against Sigma receptors that remain untested, some of which, intrigu-
ingly, have begun to appear in other studies, although not recognized 
as Sigma ligands53,54. Therefore, this area of pharmacology has great 
promise for repurposing and for the optimization of new agents in the 
fight against COVID-19.
Our approach of host-directed intervention as an antiviral strategy 
overcomes problems associated with drug resistance and may also 
provide pan-viral therapies as we prepare for the next pandemic. 
Furthermore, the possibilities for co-therapies are expanded, for 
example with drugs directly targeting the virus, including remdesivir, 
and, as we demonstrate in this study, a rich set of repurposing oppor-
tunities are illuminated. More broadly, the pipeline described here 
represents a new approach for drug discovery not only for pan-viral 
strategies, but for many diseases, and illustrates the speed in which 
science can be moved forward using a multi-disciplinary and col-
laborative approach.
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Fig. 1 | AP-MS workflow for identification of SARS-CoV-2 host 
protein-protein interactions. (a) SARS-CoV-2 genome annotation, color 













Fig. 2 | Global analysis of SARS-CoV-2 protein interactions. (a) Overview of 
global analyses performed. (b) Gene Ontology (GO) enrichment analysis was 
performed on the human interacting proteins of each viral protein, p-values 
calculated by hypergeometric test and a false discovery rate was used to 
account for multiple hypothesis testing (Methods). The top GO term of each 
viral protein was selected for visualization. (c) Degree of differential protein 
expression for the human interacting proteins (n=332) across human tissues. 
We obtained protein abundance values for the proteome in 29 human tissues 
and calculated the median level of abundance for the human interacting 
proteins (top 16 tissues shown). This was then compared with the abundance 
values for the full proteome in each tissue and summarized as a Z-score from 
which a p-value was calculated and false discovery rate was used to account for 
multiple hypothesis testing. (d) The distribution of correlation of protein level 
changes during SARS-CoV-2 infection for pairs of viral-human proteins (median 
is shown) is higher than non-interacting pairs of viral-human proteins 
(p-value=4.8e-05, Kolmogorov–Smirnov test) The violin plots show each viral 
to human protein correlation for preys (n=210, min=-0.986, max=0.999,  
Q1=-0.468, Q2=0.396, Q3=0.850) and non-preys (n=54765, min= -0.999, 
max=0.999, Q1=-0.599, Q2=0.006, Q3=0.700). (e) Significance of the overlap 
of human interacting proteins between SARS-CoV-2 and other pathogens using 
a hypergeometric test (unadjusted for multiple testing). The background gene 
set for the test consisted of all unique proteins detected by mass spectrometry 














Fig. 3 | SARS-CoV-2 protein-protein interaction network. 332 
high-confidence interactions between 26 SARS-CoV-2 proteins (red diamonds) 
and human proteins (circles; drug targets: orange; protein complexes: yellow; 
proteins in the same biological process: blue). Edge color proportional to MiST 
score; edge thickness proportional to spectral counts. Physical interactions 
among host proteins (thin black lines) were curated from CORUM, IntAct, and 
Reactome. An interactive PPI map can be found at kroganlab.ucsf.edu/












Fig. 4 | The SARS-CoV-2 interactome reveals novel aspects of SARS-CoV-2 
biology and pharmacological targets. (a) Orf6 interacts with an mRNA 
nuclear export complex that (i) can be targeted by Selinexor. (ii) 
Carboxy-terminal peptide of SARS-CoV-2 Orf6 (dark purple) modeled into the 
binding site of the VSV M protein (yellow)-NUP98 (green)-RAE1 (light purple) 
complex (PDB ID: 4OWR). Orf6 and M protein residues labeled. (iii) C-terminal 
sequence of SARS-CoV-2 Orf6, highlighting described trafficking motifs and 
putative NUP98-RAE1 binding sequence. Chemical properties of amino acids: 
polar (green), neutral (purple), basic (blue), acidic (red), and hydrophobic 
(black). (iv) Putative NUP98-RAE1 interaction motifs (negatively charged 
residues (red) surrounding a conserved methionine (yellow)) from several viral 
species. (b) Protein N targets stress granule (SG) proteins (i). (ii) Inhibition of 
Casein kinase II (silmitasertib or TMCB) disrupting SGs. (iii) Translation 
initiation inhibition: MNK inhibitor (tomivosertib) prevents phosphorylation 
of eIF4E; 4ER1Cat blocks the interaction of eIF4E with eIF4G. Inhibition of eIF4A 
(zotatifin) may prevent unwinding of the viral 5' UTR to thwart its translation. 
Targeting translation elongation factor-1A ternary complex (ternatin-4) or (iv) 
Sec61 translocon (PS3061) can prevent viral protein production and membrane 
insertion, respectively. (c) Orf10 interacts with the CUL2ZYG11B complex (i). (ii) 
Orf10 predicted secondary structure. (iii) Orf10 might hijack CUL2ZYG11B for 
ubiquitination of host proteins which can be inhibited by pevonedistat. (d) 
Envelope (E) protein interacts with bromodomain proteins (i). (ii) Alignment of 
proteins E of SARS-CoV-2, SARS-CoV and bat CoV with histone H3 and NS1 
protein of Influenza A H3N2. Identical and similar amino acids are highlighted. 
(iii) Bromodomain inhibitors (iBETs) might disrupt the interaction between 
protein E and BRDs. Figure shows FDA approved drugs (green), clinical 














Fig. 5 | Drug-human target network. PPIs of SARS-CoV-2 baits with approved drugs (green), clinical candidates (yellow), and preclinical candidates (purple) with 













Fig. 6 | The anti-viral activity of the translation inhibitors and Sigma 
receptor ligands. (a) Schema of viral infectivity assays. (b) The mRNA 
translation inhibitors (zotatifin, ternatin 4) reduce viral infectivity in a 
concentration-dependent matter (viral infectivity: red, Anti-NP or Plaque 
assay, blue, qRT-PCR; cell viability: black, with the initial decline likely 
reflecting cytostatic and not cytotoxic effects). Data=mean±SD; n=6 
biologically independent samples for cell viability data and DMSO controls 
from Paris; all others n=3. (c) Sigma drugs and preclinical molecules inhibit 
viral infectivity (colored as in b). Data=mean±SD; n=3 biologically independent 
samples. (d) TCID50 assays using zotatifin, PB28 and hydroxychloroquine (e) 
Drugs added before or after high titer virus (MOI=2) had similar antiviral 
effects (viral infectivity: Anti-NP). Data=mean±SD; n=3 biologically 
independent samples. (f) SigmaR1 and SigmaR2 are the common targets of the 
Sigma ligands at the 1 μM activity threshold56. (g) Dextromethorphan increases 
viral titers (viral titer TCID50: red; cell viability: black). Data=mean±SD; n=3 
biologically independent samples. (h) SigmaR1/R2 on-target Kd values vs. 
those for the hERG ion channel. PB28 and PD-144418 show 500 to 5000-fold, 
while chloroquine and hydroxychloroquine ~30-fold selectivity between these 
targets. pKi values for hERG vs. SigmaR1 vs. SigmaR2 are: chloroquine (5.5±0.1; 
7.1±0.1; 6.3±0.1); hydroxychloroquine (5.6±0.2; 6.9±0.2; 6.0±0.1); PB28 (6.0±0 
.1; 8.7±0.1; 8.6±0.1); PD-144418 (5.0±0.2; 8.7±0.1; 6.1±0.1); clemastine (6.8±0.2; 
8.0±0.1; 7.6±0.1). All data are shown as mean±SD; PB28, clemastine, PD-144418 
n=9 biologically independent samples for SigmaR1/R2 and hERG; chloroquine, 
















The genbank sequence for SARS-CoV-2 isolate 2019-nCoV/
USA-WA1/2020, accession MN985325, was downloaded on January 
24, 2020. In total, we annotated 29 possible open reading frames and 
proteolytically mature proteins encoded by SARS-CoV-21,12. Proteolytic 
products resulting from Nsp3 and Nsp5-mediated cleavage of the Orf1a 
/ Orf1ab polyprotein were predicted based on the protease specificity of 
SARS-CoV proteases57, and 16 predicted nonstructural proteins (Nsps) 
were subsequently cloned (Nsp1-Nsp16). For the Nsp5 protease (3Clike 
/ 3CLpro), we also designed the catalytic mutant Nsp5 C145A58,59. Open 
reading frames at the 3’ end of the viral genome annotated in the original 
genbank file included 4 structural proteins: S, E, M, N, and the addi-
tional open reading frames Orf3a, Orf6, Orf7a, Orf8, and Orf10. Based 
on analysis of open reading frames in the genome and comparisons 
with other annotated SARS-CoV open reading frames, we annotated 
a further four open reading frames: Orf3b, Orf7b, Orf9b, and Orf9c.
Cloning
Open reading frames and proteolytically mature Nsps annotated in the 
SARS-CoV-2 genome were human codon optimized using the IDT codon 
optimization tool (https://www.idtdna.com/codonopt) and internal 
EcoRI and BamHI sites eliminated. Start and stop codons were added 
as necessary to Nsps 1-16, a Kozak sequence was added before each 
start codon, and a 2x-Strep tag with linker was added to either the N- or 
C-terminus. To guide our tagging strategy we utilized GPS-Lipid to pre-
dict protein lipid modification on termini (http://lipid.biocuckoo.org/
webserver.php)60,61, TMHMM Server v. 2.0 to predict transmembrane 
/ hydrophobic regions (http://www.cbs.dtu.dk/services/TMHMM/)62, 
and SignalP v. 5.0 to predict signal peptides (http://www.cbs.dtu.dk/ser-
vices/SignalP/)63. IDT gBlocks were ordered for all reading frames with 
15-bp overlaps corresponding to flanking sequences of the EcoRI and 
BamHI restriction sites in the lentiviral constitutive expression vector 
pLVX-EF1alpha-IRES-Puro (Takara). Vectors were digested and gel puri-
fied, and gene fragments were cloned using InFusion (Takara). The Spike
protein was synthesized and cloned into pTwist-EF1alpha-IRES-Puro 
(Twist Biosciences). Nsp16 displayed multiple mutations which could 
not be repaired prior to the time-sensitive preparation of this manu-
script, and Nsp3 was too large to be synthesized in time to be included 
in this study. Strep-tagged constructs encoding Nsp3, Nsp3 C857A 
(catalytic mutant), and Nsp16 will be used in future AP-MS experiments.
Cell culture
HEK293T/17 cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(Corning) supplemented with 10% Fetal Bovine Serum (Gibco, Life 
Technologies) and 1% Penicillin-Streptomycin (Corning) and main-
tained at 37 °C in a humidified atmosphere of 5% CO2. HEK-293T/17 
cells were procured from the UCSF Cell Culture Facility, now available 
through UCSF's Cell and Genome Engineering Core ((https://cgec.
ucsf.edu/cell-culture-and-banking-services); cell line collection listed 
here: https://ucsf.app.box.com/s/6xkydeqhr8a2xes0mbo2333i3k1ln
dqv (CCLZR076)). STR analysis by the Berkeley Cell Culture Facility on 
August 8, 2017 authenticates HEK-293T/17 cells with 94% probability. 
Cells were tested on July 3, 2019 using the MycoAlertTM Mycoplasma 
Detection Kit (Lonza LT07-318) and were negative: B/A ratio < 1 (no 
detected mycoplasma).
Transfection
For each affinity purification (26 wild-type and one catalytically dead 
SARS-CoV-2 baits, one GFP control, one empty vector control), ten mil-
lion HEK293T/17 cells were plated per 15-cm dish and transfected with 
up to 15 μg of individual Strep-tagged expression constructs after 20-24 
hours. Total plasmid was normalized to 15 μg with empty vector and 
complexed with PolyJet Transfection Reagent (SignaGen Laboratories) 
at a 1:3 μg:μl ratio of plasmid to transfection reagent based on manu-
facturer’s recommendations. After more than 38 hours, cells were 
dissociated at room temperature using 10 ml Dulbecco’s Phosphate 
Buffered Saline without calcium and magnesium (D-PBS) supplemented 
with 10 mM EDTA for at least 5 minutes and subsequently washed with 
10 ml D-PBS. Each step was followed by centrifugation at 200 xg, 4 °C 
for 5 minutes. Cell pellets were frozen on dry ice and stored at -80 °C. 
For each bait, n=3 independent biological replicates were prepared 
for affinity purification.
Affinity purification
Frozen cell pellets were thawed on ice for 15-20 minutes and suspended 
in 1 ml Lysis Buffer [IP Buffer (50 mM Tris-HCl, pH 7.4 at 4 °C, 150 mM 
NaCl, 1 mM EDTA) supplemented with 0.5% Nonidet P 40 Substitute 
(NP40; Fluka Analytical) and cOmplete mini EDTA-free protease and 
PhosSTOP phosphatase inhibitor cocktails (Roche)]. Samples were then 
frozen on dry ice for 10-20 minutes and partially thawed at 37 °C before 
incubation on a tube rotator for 30 minutes at 4 °C and centrifugation 
at 13,000 xg, 4 °C for 15 minutes to pellet debris. After reserving 50 μl 
lysate, up to 48 samples were arrayed into a 96-well Deepwell plate for 
affinity purification on the KingFisher Flex Purification System (Thermo 
Scientific) as follows: MagStrep “type3” beads (30 μl; IBA Lifesciences) 
were equilibrated twice with 1 ml Wash Buffer (IP Buffer supplemented 
with 0.05% NP40) and incubated with 0.95 ml lysate for 2 hours. Beads 
were washed three times with 1 ml Wash Buffer and then once with 1 ml IP 
Buffer. To directly digest bead-bound proteins as well as elute proteins 
with biotin, beads were manually suspended in IP Buffer and divided 
in half before transferring to 50 μl Denaturation-Reduction Buffer 
(2 M urea, 50 mM Tris-HCl pH 8.0, 1 mM DTT) and 50 μl 1x Buffer BXT 
(IBA Lifesciences) dispensed into a single 96-well KF microtiter plate, 
respectively. Purified proteins were first eluted at room temperature 
for 30 minutes with constant shaking at 1,100 rpm on a ThermoMixer 
C incubator. After removing eluates, on-bead digestion proceeded 
(below). Strep-tagged protein expression in lysates and enrichment 
in eluates were assessed by western blot and silver stain, respectively. 
The KingFisher Flex Purification System was placed in the cold room 
and allowed to equilibrate to 4 °C overnight before use. All automated 
protocol steps were performed using the slow mix speed and the fol-
lowing mix times: 30 seconds for equilibration/wash steps, 2 hours 
for binding, and 1 minute for final bead release. Three 10 second bead 
collection times were used between all steps.
On-bead digestion
Bead-bound proteins were denatured and reduced at 37 °C for 30 min-
utes and after bringing to room temperature, alkylated in the dark with 
3 mM iodoacetamide for 45 minutes and quenched with 3 mM DTT for 
10 minutes. Proteins were then incubated at 37 °C, initially for 4 hours 
with 1.5 μl trypsin (0.5 μg/μl; Promega) and then another 1-2 hours with 
0.5 μl additional trypsin. To offset evaporation, 15 μl 50 mM Tris-HCl, 
pH 8.0 were added before trypsin digestion. All steps were performed 
with constant shaking at 1,100 rpm on a ThermoMixer C incubator. 
Resulting peptides were combined with 50 μl 50 mM Tris-HCl, pH 8.0 
used to rinse beads and acidified with trifluoroacetic acid (0.5% final, 
pH < 2.0). Acidified peptides were desalted for MS analysis using a 
BioPureSPE Mini 96-Well Plate (20mg PROTO 300 C18; The Nest Group, 
Inc.) according to standard protocols.
Mass spectrometry data acquisition and analysis
Samples were re-suspended in 4% formic acid, 2% acetonitrile solution, 
and separated by a reversed-phase gradient over a nanoflow C18 column 
(Dr. Maisch). Each sample was directly injected via a Easy-nLC 1200 
(Thermo Fisher Scientific) into a Q-Exactive Plus mass spectrometer 
(Thermo Fisher Scientific) and analyzed with a 75 min acquisition, with 
all MS1 and MS2 spectra collected in the orbitrap; data were acquired 













3006). For all acquisitions, QCloud was used to control instrument 
longitudinal performance during the project64. All proteomic data was 
searched against the human proteome (uniprot reviewed sequences 
downloaded February 28th, 2020), EGFP sequence, and the SARS-CoV-2 
protein sequences using the default settings for MaxQuant (version 
1.6.11.0)65,66. Detected peptides and proteins were filtered to 1% false 
discovery rate in MaxQuant, and identified proteins were then sub-
jected to protein-protein interaction scoring with both SAINTexpress 
(version 3.6.3)14 and MiST (https://github.com/kroganlab/mist)15,67. 
We applied a two-step filtering strategy to determine the final list of 
reported interactors which relied on two different scoring stringency 
cutoffs. In the first step, we chose all protein interactions that possess 
a MiST score ≥ 0.7, a SAINTexpress BFDR ≤ 0.05 and an average spec-
tral count ≥ 2. For all proteins that fulfilled these criteria we extracted 
information about stable protein complexes they participate in from 
the CORUM68 database of known protein complexes. In the second step 
we then relaxed the stringency and recovered additional interactors 
that (1) form complexes with interactors determined in filtering step 
1 and (2) fulfill the following criteria: MiST score ≥ 0.6, SAINTexpress 
BFDR ≤ 0.05 and average spectral counts ≥ 2. Proteins that fulfilled 
filtering criteria in either step 1 or step 2 were considered to be HC-PPIs 
and visualized with Cytoscape (version 3.7.1)69. Using this filtering 
criteria, nearly all of our baits recovered a number of HC-PPIs in close 
alignment with previous datasets reporting an average of ~6 PPIs per 
bait70. However, for a subset of baits (Orf8, Nsp8, Nsp13, and Orf9c) we 
observed a much higher number of PPIs passing these filtering criteria. 
For these four baits, the MiST scoring was instead performed using a 
larger in-house database of 87 baits that were prepared and processed 
in an analogous manner to this SARS-CoV-2 dataset. This was done to 
provide a more comprehensive collection of baits for comparison, to 
minimize the classification of non-specifically binding background 
proteins as HC-PPIs. All mass spectrometry raw data and search results 
files have been deposited to the ProteomeXchange Consortium via the 
PRIDE partner repository with the dataset identifier PXD01811771,72. PPI 
networks have also been uploaded to NDEx.
Gene ontology over-representation analysis
The targets of each bait were tested for enrichment of Gene Ontology 
(GO Biological Process) terms. The over-representation analysis (ORA) 
was based on the hypergeometric distribution and performed using the 
enricher function of clusterProfiler package in R with default param-
eters. The gene ontology terms were obtained from the c5 category 
of Molecular Signature Database (MSigDBv6.1). Significant GO terms 
(1% FDR) were identified and further refined to select non-redundant 
terms. In order to select non-redundant gene sets, we first constructed 
a GO term tree based on distances (1-Jaccard Similarity Coefficients 
of shared genes) between the significant terms. The GO term tree was 
cut at a specific level (h=0.99) to identify clusters of non-redundant 
gene sets. For a bait with multiple significant terms belonging to the 
same cluster, we selected the broadest term i.e. largest gene set size.
Virus interactome similarity analysis
Interactome similarity was assessed by comparing the number of shared 
human interacting proteins between pathogen pairs, using a hypergeo-
metric test to calculate significance. The background gene set for the 
test consisted of all unique proteins detected by mass spectrometry 
across all pathogens (N=10,181 genes).
Orf6 peptide modeling
The proposed interaction between Orf6 and the NUP98-RAE1 com-
plex was modeled in PyRosetta 473 (release v2020.02-dev61090) using 
the crystal structure of Vesicular stomatitis virus matrix (M) protein 
bound to NUP98-RAE1 as a template32 (PDB 4OWR downloaded from 
the PDB-REDO server74). The M protein chain (C) was truncated after 
residue 54 to restrict the model to the putative interaction motif in Orf6 
(M protein residues 49-54, sequence DEMDTH). These residues were 
mutated to the Orf6 sequence, QPMEID, using the mutate_residue func-
tion in the module pyrosetta.toolbox, without repacking at this initial 
step. After all six residues were mutated, the full model was relaxed to 
a low energy conformation using the FastRelax protocol in the module 
pyrosetta.rosetta.protocols.relax. FastRelax was run with constraints 
to starting coordinates and scored with the ref2015 score function. 
The resulting model was inspected for any large energetic penalties 
associated with the modeled peptide residues or those NUP98 and 
RAE1 residues interacting with the peptide, and was found to have none. 
The model was visualized in PyMOL (The PyMOL Molecular Graphics 
System, Version 2.3.4 Schrödinger, LLC.).
Orf10 secondary structure prediction
The secondary structure of Orf10 was predicted using JPRED (https://
www.compbio.dundee.ac.uk/jpred/index.html)75.
Protein E alignment
Protein E sequences from SARS-CoV-2 (YP_009724392.1), SARS-CoV 
(NP_828854.1), and bat SARS-like CoV (AGZ48809.1) were aligned using 
Clustal Omega76, and then manually aligned to the sequences of histone 
H3 (P68431) and Influenza A H3N2 NS1 (YP_308845.1).
Chemoinformatic analysis of SARS-CoV-2 interacting partners
To identify drugs and reagents that modulate the 332 host factors 
interacting with SARS-CoV-2-HEK293T/17 (MiST >= 0.70), we used 
two approaches: 1) a chemoinformatic analysis of open-source chemi-
cal databases and 2) a target- and pathway-specific literature search, 
drawing on specialist knowledge within our group. Chemoinformati-
cally, we retrieved 2,472 molecules from the IUPHAR/BPS Guide to 
Pharmacology (2020-3-12)56 (Supplementary Table 7) that interacted 
with 30 human "prey" proteins (38 approved, 71 in clinical trials), and 
found 10,883 molecules (95 approved, 369 in clinical trials) from the 
ChEMBL25 database77 (Supplementary Table 8). For both approaches, 
molecules were prioritized on their FDA approval status, activity at the 
target of interest better than 1 μM, and commercial availability, draw-
ing on the ZINC database78. FDA approved molecules were prioritized 
except when clinical candidates or preclinical research molecules had 
substantially better selectivity or potency on-target. In some cases, 
we considered molecules with indirect mechanisms of action on the 
general pathway of interest based solely on literature evidence (e.g., 
captopril modulates ACE2 indirectly via its direct interaction with 
Angiotensin Converting Enzyme, ACE). Finally, we predicted 6 addi-
tional molecules (2 approved, 1 in clinical trials) for proteins with MIST 
scores between 0.7-0.6 to viral baits (Supplementary Tables 4 and 5). 
Complete methods can be found here (https://github.com/momeara/
BioChemPantry/tree/master/vignette/COVID19).
Molecular docking
After their chemoinformatic assignment to the Sigma1 receptor, clo-
perastine and clemastine were docked into the agonist-bound state 
structure of the receptor (6DK1)79 using DOCK3.780. The best scoring 
configurations that ion-pair with Glu172 are shown; both l-cloperastine 
and clemastine receive solvation-corrected docking scores between 
-42 and -43 kcal/mol, indicating high complementarity.
Viral growth and cytotoxicity assays in the presence of 
inhibitors (Mt. Sinai)
2,000 Vero E6 cells were seeded into 96-well plates in DMEM (10% FBS) 
and incubated for 24 h at 37C, 5% CO2. Vero E6 cells used were purchased 
from ATCC and thus authenticated (VERO C1008 [Vero 76, clone E6, Vero 
E6] (ATCC® CRL-1586™); tested negative for mycoplasma contamination 
prior to commencement). Two hours before infection, the medium was 
replaced with 100ul of DMEM (2% FBS) containing the compound of 













a DMSO control. The Vero E6 cell line used in this study is a kidney cell 
line; therefore, we cannot exclude that lung cells yield different results 
for some inhibitors (also see Methods Institut Pasteur). Plates were then 
transferred into the BSL3 facility and 100 PFU (MOI 0.025) was added 
in 50ul of DMEM (2% FBS), bringing the final compound concentration 
to those indicated. Plates were then incubated for 48 h at 37C. After 
infection, supernatants were removed and cells were fixed with 4% for-
maldehyde for 24 hours prior to being removed from the BSL3 facility. 
The cells were then immunostained for the viral NP protein (anti-sera 
produced in the Garcia-Sastre lab; 1:10,000) with a DAPI counterstain. 
Infected cells (488nM) and total cells (DAPI) were quantified using 
the Celigo (Nexcelcom) imaging cytometer. Infectivity is measured 
by the accumulation of viral NP protein in the nucleus of the Vero E6 
cells (fluorescence accumulation). Percent infection was quantified as 
((Infected cells/Total cells) - Background) *100 and the DMSO control 
was then set to 100% infection for analysis. The IC50 and IC90 for each 
experiment were determined using the Prism (GraphPad Software) 
software. For select inhibitors, infected supernatants were assayed for 
infectious viral titer using the Median Tissue Culture Infectious Dose 
(TCID)50 method. For this, infectious supernatants were collected at 
48h post infection and frozen at −80 °C until later use. Infectious titers 
were quantified by limiting dilution titration on Vero E6 cells. Briefly, 
Vero E6 cells were seeded in 96-well plates at 20,000 cells/well. The 
next day, SARS-CoV-2-containing supernatant was applied at serial 
10-fold dilutions ranging from 10−1 to 10−6 and, after 5 days, viral CPE
was detected by staining cell monolayers with crystal violet. TCID50/mL
were calculated using the method of Reed and Muench. Cytotoxicity 
was also performed using the MTT assay (Roche), according to the 
manufacturer’s instructions. Cytotoxicity was performed in uninfected 
VeroE6 cells with same compound dilutions and concurrent with viral 
replication assay. All assays were performed in biologically independ-
ent triplicates.
Cells and viruses (Institut Pasteur)
African green monkey kidney epithelial Vero E6 (ATCC, CRL-1586, 
authenticated by ATCC and tested negative for mycoplasma contamina-
tion prior to commencement [Vero 76, clone E6, Vero E6] (ATCC® CRL-
1586™)) were maintained in a humidified atmosphere at 37 °C with 5% 
CO2, in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% 
(v/v) fetal bovine serum (FBS, Invitrogen) and 5 units/mL penicillin and 
5 μg/mL streptomycin (Life Technologies). The Vero E6 cell line used in 
this study is a kidney cell line; therefore, we cannot exclude that lung 
cells yield different results for some inhibitors (also see Methods Mt. 
Sinai). SARS-CoV-2, isolate France/IDF0372/2020, was supplied by the 
National Reference Centre for Respiratory Viruses hosted by Institut 
Pasteur (Paris, France) and headed by Pr. Sylvie van der Werf. The human 
sample from which strain BetaCoV/France/IDF0372/2020 was iso-
lated has been provided by Dr. X. Lescure and Pr. Y. Yazdanpanah from 
the Bichat Hospital, Paris, France. he BetaCoV/France/IDF0372/2020 
strain was supplied through the European Virus Archive goes Global 
(Evag) platform, a project that has received funding from the European 
Union's Horizon 2020 research and innovation programme under the 
grant agreement No 653316. Viral stocks were prepared by propaga-
tion in Vero E6 cells in DMEM supplemented with 2% FBS and 1 μg/ml 
TPCK-trypsin (Sigma-Aldrich). Viral titers were determined by plaque 
assay in Minimum Essential Media supplemented with 2% (v/v) FBS (Inv-
itrogen) and 0.05% agarose. All experiments involving live SARS-CoV-2 
were performed at Institut Pasteur Paris (IPP) in compliance with IPP’s 
guidelines following Biosafety Level 3 (BSL-3) containment procedures 
in approved laboratories. All experiments were performed in at least 
three biologically independent samples.
Antiviral activity assays (Institut Pasteur)
Vero E6 cells were seeded at 1.5x104 cells per well in 96-well plates 18h 
prior to the experiment. Two hours prior to infection, the cell culture 
supernatant of triplicate wells was replaced with media containing 
10 μM, 2 μM, 500 nM, 200 nM, 100 nM or 10 nM of each compound or the 
equivalent volume of maximum DMSO vehicle used as a control. At the 
time of infection, the drug-containing media was removed, and replaced 
with virus inoculum (MOI of 0.1 PFU/cell) containing TPCK-trypsin 
(Sigma-Aldrich). Following a one-hour adsorption at 37 °C, the virus 
inoculum was removed and 200μL of drug- (or vehicle-) containing 
media added. 48h post infection (p.i.), the cell culture supernatant was 
used to extract RNA using the Direct-zol-96 RNA extraction kit (Zymo) 
following the manufacturer’s instructions. Detection of viral genomes 
in the extracted RNA was performed by RT-qPCR, using previously pub-
lished SARS-CoV-2 specific primers81. Specifically, the primers target 
the N gene region: 5′-TAATCAGACAAGGAACTGATTA-3′ (Forward) and 
5′-CGAAGGTGTGACTTCCATG-3′ (Reverse). RT-qPCR was performed 
using the Luna Universal One-Step RT-qPCR Kit (NEB) in an Applied 
Biosystems QuantStudio 6 thermocycler, using the following cycling 
conditions: 55 °C for 10 min, 95 °C for 1 min, and 40 cycles of 95 °C for 
10 sec, followed by 60 °C for 1 min. The quantity of viral genomes is 
expressed as PFU equivalents, and was calculated by performing a 
standard curve with RNA derived from a viral stock with a known viral 
titer. In addition to measuring viral RNA in the supernatant derived 
from drug-treated cells, infectious virus was quantified by plaque assay.
Cell viability assays (Institut Pasteur)
Cell viability in drug-treated cells was measured using AlamarBlue reagent 
(ThermoFisher). Briefly, 48 h post treatment, the drug-containing media 
was removed and replaced with AlamarBlue and incubated for 1h at 37 °C 
and fluorescence measured in a Tecan Infinity 2000 plate reader. Percent-
age viability was calculated relative to untreated cells (100% viability) 
and cells lysed with 20% ethanol (0% viability), included in each plate.
Plaque assays (Institut Pasteur)
Viruses were quantified by plaque assays. For this, Vero E6 cells were 
seeded in 24-well plates at a concentration of 7.5x 104 cells per well. The 
following day, 10-fold serial dilutions of individual virus samples in 
serum-free MEM media were added to infect the cells at 37 °C for 1 hour. 
After the adsorption time the overlay media was added at final concentra-
tion of 2% FBS / MEM media and 0.05% Agarose to achieve a semi-solid 
overlay. Plaque assays were incubated at 37 °C for 3 days before fixation 
with 4% formalin and visualization using crystal violet solution.
Off-target assays for Sigma receptor drugs and ligands
hERG binding assays were carried out as previously described82. Briefly, 
compounds were incubated with hERG membranes, prepared from 
HEK293 cells stably expressing hERG channels, and [3H]-Dofetilide 
(5 nM final) in a total of 150 ul for 90 min at room temperature in the 
dark. Reactions were stopped by filtering the mixture onto a glass fiber, 
quickly washed three times to remove unbound [3H]-Dofetilide. The 
filter was dried in a microwave, melted with a scintillant cocktail, and 
wrapped in a plastic film. Radioactivity was counted on a MicroBeta 
counter and results were analyzed in Prism by fitting to the built-in 
one binding function to obtain affinity Ki. Radioligand binding assays 
for the muscarinic and alpha-adrenergic receptors were performed as 
previously described83. Detailed protocols are available on the NIMH 
PDSP website at https://pdspdb.unc.edu/html/tutorials/UNC-CH%20
Protocol%20Book.pdf
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
The mass spectrometry raw data and search results files generated dur-













via the PRIDE partner repository with the dataset identifier PXD018117 
(https://www.ebi.ac.uk/pride/archive/projects/PXD018117) and PPI 
networks have also been uploaded to NDEx (https://public.ndexbio.
org/#/network/43803262-6d69-11ea-bfdc-0ac135e8bacf). An interac-
tive version of these networks, including relevant drug and functional 
information, can be found at the following website: http://kroganlab.
ucsf.edu/network-maps. All data generated or analysed during this 
study are included in this published article (and its Supplementary 
Information files and as Source Data). Expression vectors used in this 
study are readily available from the authors to biomedical researchers 
and educators in the non-profit sector.
Code availability
Complete methods for chemoinformatic analysis can be found here 
(https://github.com/momeara/BioChemPantry/tree/master/vignette/
COVID19); details on MIST scoring can be found here (https://github.
com/kroganlab/mist).
57. Yang, D. & Leibowitz, J. L. The structure and functions of coronavirus genomic 3’ and 5'
ends. Virus Res. 206, 120–133 (2015).
58. Yang, H. et al. The crystal structures of severe acute respiratory syndrome virus main 
protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U. S. A. 100, 13190–13195
(2003).
59. Thiel, V. et al. Mechanisms and enzymes involved in SARS coronavirus genome 
expression. J. Gen. Virol. 84, 2305–2315 (2003).
60. Xie, Y. et al. GPS-Lipid: a robust tool for the prediction of multiple lipid modification sites.
Sci. Rep. 6, 28249 (2016).
61. Ren, J. et al. CSS-Palm 2.0: an updated software for palmitoylation sites prediction.
Protein Eng. Des. Sel. 21, 639–644 (2008).
62. Krogh, A., Larsson, B., von Heijne, G. & Sonnhammer, E. L. Predicting transmembrane
protein topology with a hidden Markov model: application to complete genomes. 
J. Mol. Biol. 305, 567–580 (2001).
63. Almagro Armenteros, J. J. et al. SignalP 5.0 improves signal peptide predictions using
deep neural networks. Nat. Biotechnol. 37, 420–423 (2019).
64. Chiva, C. et al. QCloud: A cloud-based quality control system for mass 
spectrometry-based proteomics laboratories. PLoS One 13, e0189209 (2018).
65. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized 
p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 
26, 1367–1372 (2008).
66. Cox, J. et al. Accurate Proteome-wide Label-free Quantification by Delayed Normalization
and Maximal Peptide Ratio Extraction, Termed MaxLFQ. Mol. Cell. Proteomics 13, 
2513–2526 (2014).
67. Verschueren, E. et al. Scoring Large-Scale Affinity Purification Mass Spectrometry
Datasets with MiST. Curr. Protoc. Bioinformatics 49, 8.19.1–16 (2015).
68. Giurgiu, M. et al. CORUM: the comprehensive resource of mammalian protein 
complexes-2019. Nucleic Acids Res. 47, D559–D563 (2019).
69. Shannon, P. et al. Cytoscape: a software environment for integrated models of
biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
70. Huttlin, E. L. et al. The BioPlex Network: A Systematic Exploration of the Human
Interactome. Cell 162, 425–440 (2015).
71. Vizcaíno, J. A. et al. ProteomeXchange provides globally coordinated proteomics data
submission and dissemination. Nat. Biotechnol. 32, 223–226 (2014).
72. Deutsch, E. W. et al. The ProteomeXchange consortium in 2017: supporting the cultural 
change in proteomics public data deposition. Nucleic Acids Res. 45, D1100–D1106 (2017).
73. Chaudhury, S., Lyskov, S. & Gray, J. J. PyRosetta: a script-based interface for implementing
molecular modeling algorithms using Rosetta. Bioinformatics 26, 689–691 (2010).
74. Joosten, R. P., Long, F., Murshudov, G. N. & Perrakis, A. The PDB_REDO server for
macromolecular structure model optimization. IUCrJ 1, 213–220 (2014).
75. Drozdetskiy, A., Cole, C., Procter, J. & Barton, G. J. JPred4: a protein secondary structure
prediction server. Nucleic Acids Res. 43, W389–94 (2015).
76. Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence
alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011).
77. Gaulton, A. et al. The ChEMBL database in 2017. Nucleic Acids Res. 45, D945–D954 (2017).
78. Sterling, T. & Irwin, J. J. ZINC 15—Ligand Discovery for Everyone. J. Chem. Inf. Model. 55, 
2324–2337 (2015).
79. Schmidt, H. R., Betz, R. M., Dror, R. O. & Kruse, A. C. Structural basis for σ receptor ligand
recognition. Nat. Struct. Mol. Biol. 25, 981–987 (2018).
80. Mysinger, M. M. & Shoichet, B. K. Rapid context-dependent ligand desolvation in
molecular docking. J. Chem. Inf. Model. 50, 1561–1573 (2010).
81. Chu, D. K. W. et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an
Outbreak of Pneumonia. Clin. Chem. 66, 549–555 (2020).
82. Huang, X.-P., Mangano, T., Hufeisen, S., Setola, V. & Roth, B. L. Identification of human
Ether-à-go-go related gene modulators by three screening platforms in an academic 
drug-discovery setting. Assay Drug Dev. Technol. 8, 727–742 (2010).
83. Besnard, J. et al. Automated design of ligands to polypharmacological profiles. Nature
492, 215–220 (2012).
Acknowledgements We thank Joshua Sarlo for his artistic contributions to the manuscript, 
Andy Kruse for his advice on Sigma receptor functional activity and pharmacologically related 
enzymes, and Steve Worland and eFFECTOR Therapeutics for providing zotatifin. This research 
was funded by grants from the National Institutes of Health (P50AI150476, U19AI135990, 
U19AI135972, R01AI143292, R01AI120694, P01A1063302, and R01AI122747 to N.J.K.; 
R35GM122481 to B.K.S.; 1R01CA221969 and 1R01CA244550 to K.M.S.; K08HL124068 to J.S.C.; 
1F32CA236347-01 to J.E.M., NIMH Psychoactive Drug Screening Contract to B.L.R.); from the 
Defense Advance Research Projects Agency HR0011-19-2-0020 (to B.K.S., N.J.K., A. G-S., 
K.M.S., D.A.A., & K.M.V.); by CRIP (Center for Research for Influenza Pathogenesis), a NIAID 
supported Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # 
HHSN272201400008C) and by supplements to NIAID grant U19AI135972 and DoD grant 
W81XWH-19-PRMRP-FPA to A.G.-S.; by the Laboratoire d'Excellence “Integrative Biology of 
Emerging Infectious Diseases” (grant ANR-10-LABX-62-IBEID) to M.V., O.S. and C.d’E.; funding 
from F. Hoffmann-La Roche and Vir Biotechnology and gifts from The Ron Conway Family. 
K.M.S is an investigator of the Howard Hughes Medical Institute. The views, opinions, and 
findings contained in this study are those of the authors and do not represent the official views, 
policies, or endorsement of the Department of Defense or the U.S. Government. The authors 
would like to thank Todd from FedEx for his heroic effort helping us to ship out drugs and 
SARS-CoV-2 expression constructs across the globe. We thank Randy Albrecht for support 
with BSL3 procedures. The authors acknowledge their partners and families for support in 
child care and other matters during this time.
Author contributions Study conception by NJK, DEG. Genome annotation by DEG, GMJ, and 
BJP. Molecular cloning by DEG, GMJ, JZG. Cell culture, affinity purifications and peptide 
digestion by GMJ and JX. Mass spectrometer operation and peptide search by DLS, and 
proteomics data processing by MeB, YZ, BJP, DLS and RH. Network annotation led by MeB 
with support from DEG, NJK, RMK and the appendix literature review team. Interactome 
meta analysis by PB, MeB, HB, MC, ZZCN, IB-H, DM, CH-A, TP, SBR, MCO, YC, JCJC, DJB, SK. 
Drug selection and annotation by MJO, TAT, SP, YS, ZZ, WS, ITK, JEM, JSC, KL, SAD, JL, LC, 
SV, JL-L, YiL, X-PH, YoL, PPS, NAW, DK, H-YW, KMS, BKS. Structural modeling by CJPM, KBP, 
SJG, DJS, RR, XL, SAW, MaB, FSU, TK. Live SARS-CoV-2 virus assays led by KMW (MSSM) and 
VR (Pasteur) with support from FR, TV, AMK, LM, EM, CK, NSS, DT, DS, SJF, MH. Analysis of 
SARS-CoV-2 genomic diversity by MalS. Analysis of human gene positive selection by JMY, 
BM, HSM. Nsp5 cleavage prediction and analysis by MaB and CC with support from DEG. 
Figure preparation by DEG, MeB, KO, KMW, MJO, DLS TAT, RH, RMK, MK, HB, YZ, ZZ, CJPM, 
TP, SAW, MaB, MalS, FSU, NAW, DGF, SNF, JDG, DR, TK, PB, KMS, BKS, NJK. Appendix 
assembled by RMK with support from literature review team: KO, RH, RMK, ALR, BT, HF, JB, 
KH, MM, MK, PH, JMF, MaE, MarS, MJB, MC, MJM, QL, CJPM, TP, XL, LC, SV, JL-L, YiL, MaB, RT, 
DAC, JH, JLR, UR, AdS, JN, NJ, SM, SNF. Manuscript prepared by DEG, MeB, KO, MJO, DLS, 
TAT, RH, RMK, MaE, MarS, MJB, PB, KMS, BKS, NJK. Work supervised by RMS, ADF, OSR, KAV, 
DAA, MO, MiE, NJ, MVN, EV, AA, OS, CD’E, SM, MJ, HSM, DGF, TI, CSC, SNF, JSF, JDG, AnS, 
BLR, DR, JT, TK, PB, MV, AG-S, KMS, BKS, NJK.
Competing interests The Krogan Laboratory has received research support from Vir 
Biotechnology and F. Hoffmann-La Roche. Kevan Shokat has consulting agreements for the 
following companies involving cash and/or stock compensation: Black Diamond Therapeutics, 
BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics (zotatifin 
& tomivosertib), Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, 
Kura Oncology, Merck, Mitokinin, Petra Pharma, Qulab Inc. Revolution Medicines (WDB002), 
Type6 Therapeutics, Venthera, Wellspring Biosciences (Araxes Pharma). Jack Taunton is a 
cofounder and shareholder of Global Blood Therapeutics, Principia Biopharma, Kezar Life 
Sciences, and Cedilla Therapeutics. Jack Taunton and Phillip P. Sharp are listed as inventors 
on a patent application describing the cyclic depsipeptide, PS3061 (PCT/US2019/024731 by 
the Regents of the University of California and Kezar Life Sciences). Davide Ruggero is a 
shareholder of eFFECTOR Therapeutics, Inc., and a member of its scientific advisory board 
(zotatifin & tomivosertib). The authors have not filed for patent protection on the SARS-CoV-2 
host interactions or the use of predicted drugs for treating COVID-19 to ensure all the 
information is freely available to accelerate the discovery of a treatment.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41586-020-
2286-9.
Correspondence and requests for materials should be addressed to N.J.K.
Peer review information Nature thanks Michael P. Weekes and the other, anonymous, 
reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are 
available.














Extended Data Fig. 1 | Mutations in overlapping coding regions result in 
premature termination of Orf3a and Orf9c. (a) Table of the SARS-CoV-2 
proteins, including molecular weight, sequence similarity with the SARS-CoV 
homolog, and inferred function based on the SARS-CoV homolog.  
(b) Immunoblot detection of 2xStrep tag demonstrates expression of each 
bait in input samples, as indicated by red arrowhead. For each bait, input 
from one of the three replicates prepared and affinity purified for mass 
spectrometry was used for western blot (n=1). For gel source data, see 
Supplementary Figure 1. (c) Schematic representation of Orf3a (light green) 
and Orf3b (dark green) overlapping regions. A premature stop codon in Orf3b 
at position 14 (E14*) corresponds to a Q57H mutation in Orf3a. (d) Schematic of 
the N gene (red), Orf9b (green) and Orf9c (green) overlapping regions. Two 
mutations in the N protein (S194L and S197L) correspond to premature stop 
codons at positions 41 and 44 in Orf9c. The analysis is based on 2,784 













Extended Data Fig. 2 | Clustering analysis of AP-MS dataset reveals 
biological replicates of individual baits are well correlated. All MS runs (n=3 
biologically independent samples, run in replicates) were compared and 
clustered using artMS (David Jimenez-Morales, Alexandre Rosa Campos, and 
John Von Dollen, and Nevan Krogan. (2019). artMS: Analytical R tools for Mass 
Spectrometry. R package version 1.3.9. https://github.com/biodavidjm/
artMShttps://github.com/bio-davidjm/artMS). This figure depicts all 
Pearson’s pairwise correlations between MS runs, and is clustered according to 
similar correlation patterns. Correlation between replicates for individual 
baits ranges from 0.46-0.72, and in most cases the experiments corresponding 
to each bait cluster together, with the exception of a couple of baits with lower 














Extended Data Fig. 3 | Gene ontology biological process enrichments for 
SARS-CoV-2 host factors. We performed GO biological process enrichments 
(see Methods) for the host factors identified as binding to each SARS-CoV-2 
viral protein and represent here the top 5 most significant terms for each viral 
protein. The p-values were calculated by a hypergeometric test and a false 












Extended Data Fig. 4 | Pfam protein families enrichments for SARS-CoV-2 
host factors. The enrichment of individual PFAM domains was calculated 
using a hypergeometric test where success is defined as the number of 
domains, and the number of trials is the number of individual preys affinity 
purified with each viral bait. The population values were the numbers of 
individual PFAM domains in the human proteome. The p-values were not 
adjusted for multiple testing. To make sure that the p-values that signify 
enrichment were meaningful, we only considered PFAM domains that have 
been affinity purified at least three times with any SARS-CoV-2 protein, and 
which occur in the human proteome at least five times. Here, we show PFAM 














Extended Data Fig. 5 | Lung mRNA expression and specificity of SARS-CoV-
2-interacting human proteins relative to other proteins. (a) Scatterplot of 
the lung mRNA expression (TPM) versus enrichment of lung mRNA expression 
(lung TPM/median all tissue TPM) for human interacting proteins. Red points 
denote drug targets that are labeled with their gene names. Points above the 
horizontal blue line represent interacting proteins that are enriched in lung 
expression and show how most SARS-CoV-2 interacting proteins tend to be 
enriched in the lung. (b) Gene expression in the lung of the high-confidence 
human interacting proteins was observed to be higher when compared to all 
other proteins (blue=interacting proteins; n=332; median=25.52 TPM; grey=all 













Extended Data Fig. 6 | Candidate targets for the viral Nsp5 protease.  
(a) Nsp5 WT and Nsp5 C145A (catalytic dead mutant) interactome. 
(b) Domain maps of HDAC2 and TRMT1 illustrating predicted cleavage sites 
(using NetCorona 1.0). HDAC: Histone Deacetylase Domain, NLS: Nuclear 
Localization Sequence, MTS: Mitochondrial Targeting Sequence, SAM-MT: 
S-adenosylmethionine-Dependent Methyltransferase Domain. (c) Peptide
docking of predicted cleavage peptides into the crystal structure of SARS-CoV 















Extended Data Fig. 7 | Consensus analysis of SARS-CoV-2 Orf6 homologs. (a) 
Sequence logo of SARS-CoV-2 Orf6 homologs, showing sequence conservation 
at each position computed from a multiple sequence alignment of 35 
sequences. The key methionine M58, and the acidic residues E55, E59, and D61 
of the putative NUP98-RAE1 binding motif are shown to be highly conserved. 
Homology determined from alignments to full length sequences. Colors 
indicated chemical properties of amino acids: polar (G, S, T, Y, C, green), neutral 
(Q, N, purple), basic (K, R, H, blue), acidic (D, E, red), and hydrophobic (A, V, L, I, 
P, W, F, M, black). (b) Multiple sequence alignment of SARS-CoV-2 Orf6 
homologs. Query sequence shown at top (sequence 1 ref|YP_009724394.1). 














Extended Data Fig. 8 | Viral growth and cytotoxicity for compounds tested 
in New York. Viral growth (percent infection; red) and cytotoxicity (black) 
results for compounds tested at Mount Sinai in New York. Zotatifin, 
hydroxychloroquine, and PB28 were also tested in Median Tissue Culture 
Infectious Dose assay (TCID50; green). Zotafitin and Midostaurin were tested in 
two independent experiments and data are shown in two individual panels. 














Extended Data Fig. 9 | Virus plaque assays, qRT-PCR, and cell viability for 
compounds tested in Paris. Plaque assay (viral titer; red), qRT-PCR (viral RNA; 
blue) and cell viability (Alamar Blue; black) results for compounds tested at the 
Pasteur Institute in Paris. PF-846 was tested in two independent experiments 
and data are shown in two individual panels. Data=mean±SD; n=3 biologically 














Extended Data Fig. 10 | Activity of Sigma ligands. (a) The drugs cloperastine 
and clemastine can be readily fit into the agonist-bound structure of the Sigma1 
receptor. (b) Compounds tested for antiviral activity with annotated Sigma 1 
Receptor (SIGMAR1) and/or Sigma 2 Receptor (SIGMAR2/TMEM97) activity are 
scatter-plotted. Inhibition pIC50 values of SARS-CoV-2 infection is shown from 
blue to yellow, mode of functional activity at SIGMA1R is shown by mark shape 
(upwards triangle: agonist, downwards triangle: antagonist, circle: binding), 
and pKi values for SIGMA1R and SIGMAR2 are shown along the x- and y-axes. We 
have not yet tested chloroquine for antiviral activity. E-52862 binding at 
SIGMAR2/TMEM97 is only reported to be greater than 1 μM. Activities of 
pimozide and olanzapine at SIGMAR2/TMEM97 have not been reported. 














Extended Data Fig. 11 | Astemizole is a potent Sigma2 Receptor Ligand. 
Concentration response curves of astemizole from radio-ligand displacement 
assays for (a) the Sigma2 (95 nM IC50) and (b) the Sigma1 (1.3 uM IC50) 














Extended Data Fig. 12 | Off-target activities for characteristic Sigma 
receptor ligands. Dose response curves against a panel of eight targets that 
can confer adverse cardiac, respiratory, and dry-mouth effects for chloroquine, 
hydroxychloroquine, PB28, PD-144418, and clemastine. These results are not 
meant to represent or replace a comprehensive test against off-target panels, 
as might commonly be assayed in drug progression for clinical use. The 8 
targets include the Alpha-2A adrenergic receptors: Alpha 2A (ADRA2A), Alpha 
2B (ADRA2B), and Alpha 2C (ADRA2C); as well as the Muscarinic acetylcholine 
receptors: M1 (CHRM1), M2, (CHRM2), M3 (CHRM3), M4 (CHRM4) and M5 
(CHRM5). Data=mean±SD; all n= 3 biologically independent samples.
